Merit Medical's (MMSI) latest additions to its embolotherapy portfolio are likely to improve the patient experience.
Veeva System's (VEEV) strong product demand and strategic deals raise optimism about the stock.
Baxter's (BAX) receipt of the latest expanded indication for Clinolipid is expected to meet the diverse nutritional needs of patients, ranging from preterm neonates to adults.